GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Velsera Technology Achieves Milestone with FDA Approval of Illumina TruSight™ Oncology Comprehensive IVD, Advancing Cancer Diagnostics

NextEdge Admin

16 Sep 2024

2 min 22 sec

Illumina,precision medicine,targeted therapies

Velsera, a global leader in healthcare technology, is proud to announce that its advanced tumor profiling technology is a key component of the Illumina TruSight™ Oncology (TSO) Comprehensive IVD results report. By integrating Velsera’s cutting-edge knowledge base (KB), the TSO Comprehensive test enhances patient care through personalized treatment, providing nationwide access to precision oncology.

The collaboration between Velsera and Illumina, which began in December 2018, was driven by a mutual commitment to advancing cancer diagnostics and expanding access to targeted therapies. Velsera’s KB plays a critical role in helping laboratories adopt NGS-based diagnostics with increased accuracy and efficiency.

“Our partnership with Velsera has been instrumental in developing the TruSight™ Oncology Comprehensive test, enabling labs to simplify the identification of key cancer biomarkers,” said Nicki Berry, Head of Region-Americas at Illumina.

Velsera’s KB aids in the classification of cancer mutations, distinguishing between those with clinical or potential clinical significance. This supports more personalized treatment plans, improving patient outcomes.

“Making targeted therapeutics more accessible globally remains our priority,” said Jamie Littlejohns, CEO of Velsera. “This milestone demonstrates our dedication to translating research into real-world clinical applications that benefit cancer patients across the U.S.”

As a leader in precision medicine, Velsera continues to collaborate with industry giants like Illumina to drive innovations in cancer diagnostics. Their joint efforts accelerate the development of in vitro diagnostic (IVD) solutions, setting a new standard for biomarker identification and advancing patient care globally.